Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Conditions
Keywords
CLL, fludarabine, rituximab, dasatinib, refractory, relapsed
Brief summary
Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are similar diseases of the white blood cells and are typically treated the same way. Recent research shows that a key enzyme in CLL cells is responsible for cell survival. This enzyme is called LYN kinase. Laboratory studies show that inhibition of LYN kinase in CLL cells results in the death of CLL cells. Dasatinib has the ability to inhibit LYN kinase and, therefore, should have some effect on CLL cells. The purpose of this study is to see of the study drug dasatinib, in combination with fludarabine and rituximab, is safe and effective to use for people with relapsed or refractory CLL/SLL.
Detailed description
* Since the purpose of the study is to determine the response rate of the 3 drug regimen, everyone who participates will receive the same dose of the study drug, dasatinib and the 2 standard drugs, fludarabine and rituximab. * Participants will receive the drugs dasatinib, fludarabine, and rituximab at the following time points through each cycle of treatment. A cycle of study treatment is 28 days. Dasatinib pills will be taken orally each day for the first 2 weeks of each cycle. Fludarabine will be give intravenously on three days of each cycle (Days 3-5 in the first cycle, days 1-3 after that). Rituximab will be given intravenously with a total dose of 375 mg/m2 each cycle (split on Days 3+4 in the first cycle and at the discretion of the treating physician after that on Days 1-3). * The following procedures will be repeated throughout the study: medical history review; physical exam; performance status test; blood tests and EKG. They will occur daily during the first week of treatment, then weekly for the rest of cycle 1. After cycle 1 these procedures will be done once a week for 4 weeks then once a month for 6 months. * Tumor assessments will be repeated once every 2 months for the first six months of the study, and then once every 6 months after that. * Blood samples will be obtained in the first 5 days of treatment for pharmacokinetic studies and pharmacodynamic studies. * Participants that are benefiting from the study treatment after the first cycle can continue to receive an additional 6 cycles of study treatment.
Interventions
DRUGdasatinib
Taken orally once a day on days 1-14 of each 28-day cycle
DRUGRituximab
Given intravenously, 375 mg/m2 each cycle (dose split, given on Days 3+4 of cycle 1, variable after that).
DRUGfludarabine
Given intravenously, 25 mg/m2/day, for 3 doses per cycle (Days 3-5 in cycle 1, Days 1-3 after that)
Sponsors
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Bristol-Myers Squibb
Massachusetts General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* CLL/SLL with cells positive by flow cytometry (or immunostaining) for CD19, CD23, and CD5. Patients may be CD23 negative as long as they are also cyclin D1 negative or t(11;14) negative. * Participants must have received at least 1 prior regimen containing a purine analogue or have received at least 2 chemotherapy regimens not containing a purine analogue. Patients may be refractory to single-agent purine analogue treatment, but patients may not be refractory to a combination of purine analogue with rituximab. Patients may have received rituximab. * 18 years of age or older * Able to take oral medications * ECOG Performance Status of 2 or better * Adequate organ function to tolerate chemotherapy * Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the start of study drug administration and agree to use and utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study is stopped. * Require treatment based on 1996 NCI-WG criteria updated in 2008 by the IWCLL * Patient agrees to discontinue St. John's Wort while receiving dasatinib therapy and stop at least 5 days before starting dasatinib. * Patient agrees that IV bisphosphonates will be withheld for the first 8 weeks of dasatinib
Exclusion criteria
* Pregnant or breastfeeding women * Uncontrolled angina, congestive heart failure, or MI within 6 months * Diagnosed or suspected congenital long QT syndrome * Any history of clinically significant ventricular arrhythmias * Prolonged QTc interval on pre-entry ECG * Uncontrolled hypertension * Hypokalemia or hypomagnesemia that is not corrected prior to dasatinib administration * Patients should not be taking drugs that are generally accepted to have a risk of causing Torsades de Pointes * Known HIV positive * Known significant bleeding disorder unrelated to CLL * Any significant pleural or pericardial effusion * Patients may not have another malignancy that is uncontrolled or requires treatment within a year of starting this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response Rate | 2 years | To describe the response rate of complete response (CR) and partial response (PR) to treatment with this drug combination (SD=stable disease, PD=progressive disease) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free and Overall Survival | 2 years | To describe the progression-free and overall surivial |
| Toxicities | 2 years | Dasatinib may enhance the myelosuppression expected from fludarabine. This toxicity will be monitored with frequent CBC's. If after Day 21 of a cycle there is a grade 4 cytopenia, a dose reduction will occur in the next cycle of treatment, and that cycle cannot start until the ANC \> 1,000 and the platelets \> 25,000. There is also a risk for pleural effusions with dasatinib, but the risk will be low, since there is a break from dasatinib dosing on days 15-28 of each cycle. Nevertheless, if a grade 2 pleural effusion occurs, there will be a dose reduction in the next cycle of treatment. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dasatinib, Rituximab, Fludarabine Single-arm
dasatinib: Taken orally once a day on days 1-14 of each 28-day cycle
Rituximab: Given intravenously, 375 mg/m2 each cycle (dose split, given on Days 3+4 of cycle 1, variable after that).
fludarabine: Given intravenously, 25 mg/m2/day, for 3 doses per cycle (Days 3-5 in cycle 1, Days 1-3 after that) | 10 |
| Total | 10 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 1 |
Baseline characteristics
| Characteristic | Dasatinib, Rituximab, Fludarabine |
|---|---|
| Age, Continuous | 68 years |
| Region of Enrollment United States | 10 Participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 10 / 10 |
| serious Total, serious adverse events | 2 / 10 |
Outcome results
Primary
Response Rate
To describe the response rate of complete response (CR) and partial response (PR) to treatment with this drug combination (SD=stable disease, PD=progressive disease)
Time frame: 2 years
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Dasatinib, Rituximab, Fludarabine | Response Rate | CR | 2 Participants |
| Dasatinib, Rituximab, Fludarabine | Response Rate | PR | 2 Participants |
| Dasatinib, Rituximab, Fludarabine | Response Rate | SD | 5 Participants |
| Dasatinib, Rituximab, Fludarabine | Response Rate | PD | 1 Participants |
Secondary
Progression-Free and Overall Survival
To describe the progression-free and overall surivial
Time frame: 2 years
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Dasatinib, Rituximab, Fludarabine | Progression-Free and Overall Survival | Progression-free survival | 8.75 months |
| Dasatinib, Rituximab, Fludarabine | Progression-Free and Overall Survival | Overall survival | 24 months |
Secondary
Toxicities
Dasatinib may enhance the myelosuppression expected from fludarabine. This toxicity will be monitored with frequent CBC's. If after Day 21 of a cycle there is a grade 4 cytopenia, a dose reduction will occur in the next cycle of treatment, and that cycle cannot start until the ANC \> 1,000 and the platelets \> 25,000. There is also a risk for pleural effusions with dasatinib, but the risk will be low, since there is a break from dasatinib dosing on days 15-28 of each cycle. Nevertheless, if a grade 2 pleural effusion occurs, there will be a dose reduction in the next cycle of treatment.
Time frame: 2 years
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Dasatinib, Rituximab, Fludarabine | Toxicities | Platelets | Did not have any | 3 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Neutropenia | 3 | 3 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Neutropenia | 4 | 3 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Neutropenia | 5 | 0 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Neutropenia | Did not have any | 4 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Fatigue | 3 | 1 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Fatigue | 4 | 0 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Fatigue | 5 | 0 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Dyspnea | 4 | 0 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Fatigue | Did not have any | 9 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Dyspnea | 3 | 1 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Pleural effusion | 5 | 0 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Pleural effusion | Did not have any | 9 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Bleeding | 4 | 0 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Bleeding | 5 | 0 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Dyspnea | 5 | 0 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Dyspnea | Did not have any | 9 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Pleural effusion | 3 | 1 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Pleural effusion | 4 | 0 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Bleeding | 3 | 1 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Bleeding | Did not have any | 9 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Fever alone | 3 | 1 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Fever alone | 4 | 0 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Fever alone | 5 | 0 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Fever alone | Did not have any | 9 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Infection | 3 | 0 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Infection | 4 | 0 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Infection | 5 | 1 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Infection | Did not have any | 9 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Platelets | 3 | 4 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Platelets | 4 | 3 Participants |
| Dasatinib, Rituximab, Fludarabine | Toxicities | Platelets | 5 | 0 Participants |